Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 56-year-old man with late-onset systemic lupus erythematosus where digital gangrene was an initial manifestation, highlighting its rarity as a primary sign.

This case study describes a 4-year-old boy with juvenile dermatomyositis whose severe subcutaneous edema resisted conventional treatment, necessitating aggressive immunosuppression for disease control.

This case report presents a rare manifestation of secondary cutaneous B-cell lymphoma as erythematous macules coalescing into reticular patches on the scalp and forehead.

This source reviews various alternative therapies for vitiligo, such as khellin, 5-fluorouracil, Ginkgo biloba, and more, noting that further research is needed to confirm their effectiveness and safety.

This letter critiques a review of distant healing studies, highlighting significant methodological issues and limited evidence for its efficacy.

This article covers the VII International Congress of the Asociación Dermatológica del Caribe but provides no new research results.

This case report describes how anifrolumab, used beyond trial-eligible populations, led to significant clinical and serological recovery in a 45-year-old woman with organ-threatening systemic lupus erythematosus complicated by infection and resistant to conventional treatments like cyclophosphamide and rituximab.

Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.

In this case study, a 43-year-old male with anti-GBM disease experienced a relapse triggered by hair dye, leading to diffuse alveolar hemorrhage; managing this with plasmapheresis, intravenous immunoglobulins, and rituximab suggests rituximab may be beneficial for relapsing cases.

This study reviewed evidence on biologic drugs targeting immune cells for alopecia areata, finding mixed results: some achieved case-level hair regrowth, but controlled trials often showed limited efficacy.

In this retrospective cohort study, patients using leflunomide for primary autoimmune conditions showed a decreased risk of developing alopecia areata, while those using methotrexate, cyclosporine, and rituximab had an increased risk.

In this case report, researchers described a 16-year-old girl with severe systemic lupus erythematosus whose symptoms improved following treatment with steroids, intravenous immunoglobulin, and rituximab, highlighting that early diagnosis and treatment may lead to better outcomes in managing SLE.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

This study found that clinicians frequently prefer cyclophosphamide over rituximab for induction therapy of childhood-onset systemic lupus erythematosus and ANCA-associated vasculitis, following a high-dose regimen recommended by the NIH.

In this case study, a woman with SLE and severe alopecia showed improved hair growth using intralesional triamcinolone, PRP injections, and tacrolimus ointment, highlighting PRP as a potential adjunct therapy for inflammatory alopecia.

In this report, the author shares experiences from a six-month curricular internship, highlighting activities such as arterial pressure monitoring in a community pharmacy and addressing off-label rituximab use at a hospital, alongside discussions of hair loss treatments and nutritional supplementation for dysphagia in the elderly.

In this case report, a 40-year-old woman with systemic lupus erythematosus developed Type B Insulin Resistance Syndrome, characterized by severe hyperglycemia despite high insulin doses, requiring immunosuppressive therapy to manage refractory symptoms.

In this case report, researchers described a severe case of myelosuppression and alopecia totalis in a patient with systemic lupus erythematosus following azathioprine treatment, highlighting the importance of monitoring for these uncommon side effects.

This report describes a case of digital gangrene as an early manifestation of systemic lupus erythematosus in a 56-year-old man, highlighting it as a rare complication of late-onset SLE.

This case study reports an unusual presentation of primary cutaneous diffuse large B-cell lymphoma–leg type occurring on the upper lip of an 81-year-old woman, highlighting the need for timely recognition of atypical manifestations.

This case report describes digital gangrene as a rare primary manifestation of late-onset systemic lupus erythematosus in a 56-year-old man, with marked lesion improvement following rituximab treatment.

This narrative review discusses various impacts and management strategies for skin disease but reports no new clinical findings.

This case report documents digital gangrene as an unusual early sign of late-onset systemic lupus erythematosus in a 56-year-old man, which improved with rituximab treatment.

This case report suggests that platelet-rich plasma and hair transplantation may trigger or worsen the progression of cutaneous pseudolymphoma to lymphoma, particularly in patients with a family history.

This study observed that recognizing herpetic infection in pemphigus patients can help avoid unnecessary changes in immunosuppressive treatments for lesions wrongly presumed treatment-resistant.

This study reports various adverse effects associated with different doses and administration methods of a medical treatment, including gastrointestinal issues and hair loss, leading to modifications or discontinuations in some patients.

This clinical case report describes a 44-year-old male whose initial diagnosis of rheumatoid arthritis progressed over a decade to include systemic lupus erythematosus and Sjögren's Syndrome, highlighting the complexity of managing multiple autoimmune syndromes.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

This letter highlights the challenge of implementing ethical principles in healthcare due to society's dependence on financial systems, suggesting this may hinder public health and environmental well-being.

This study suggests that the combination of bendamustine and rituximab is at least as effective and possibly offers a better therapeutic index than other standard regimens as first-line treatment for certain lymphoma patients.